|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1000 AUD | +2.04% |
|
+7.53% | +17.65% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Corporate & Research | 6L | 8L | 10L | 8L | 15.38L | |||||
Total Assets | 29.03L | 23.02L | 25.45L | 1.11Cr | 43.59L | |||||
CAPEX | - | - | - | - | -1.54T | |||||
EBT | -16.39L | -15.76L | -17.35L | -89L | -1.66Cr | |||||
D&A | - | - | - | 1.64T | 44 | |||||
Net Income | -16.39L | -15.76L | -17.35L | -76.73L | -1.66Cr | |||||
Pharmaceutical - Epichem | 31.36L | 37.58L | 31.13L | - | - | |||||
Total Assets | 80.51L | 77.76L | 35.85L | - | - | |||||
EBT | 3L | -1L | -44.77L | - | - | |||||
Net Income | 3L | -1L | -44.77L | - | - | |||||
Inter-Segment Elimination | -71.31T | -82.03T | -2L | - | - |
Geographical Revenue Distribution History
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Sweden | - | 3L | - | - | - | |||||
USA | 1L | 2L | 1L | - | - | |||||
Australia | 7L | 17.37L | 26.87L | - | - | |||||
Total Assets | 1.1Cr | 1.01Cr | 61.3L | - | - | |||||
Switzerland | 11.3L | 10.43L | 17.28T | - | - | |||||
Others | 2L | 96.09T | 18.76T | - | - |
- Stock Market
- Equities
- NUZ Stock
- Financials Neurizon Therapeutics Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition